Sanolium Interim report 4/2021

Revenues in the fourth quarter amounted to 196.6 MSEK, representing growth of 17.6%

Support and maintenance fees constitute the largest share of the revenue. License revenues and Professional Services revenues are attributable to the development of the existing product as well as the Sussa project.

Adjusted EBITDA in the fourth quarter amounted to 28.3 (12.2) MSEK resulting in an adjusted EBITDA margin of 14.4 (7.3) %.

Employee related expenses amounted to 136.3 (129.3) MSEK, representing an increase of 5.4%. The number of full-time employees rose to 747 in the fourth quarter, an increase of 3.3 % from the comparable figure last year. Of these, 399 were employed in Sweden and 313 were women.

Depreciation and amortization amounted to 38.5 MSEK, of which 27.3 MSEK relates to amortization of intangible assets linked to M&A activities, 2.9 MSEK refers to financial leases and 5.7 MSEK refers to amortization of capitalized R&D. The remaining depreciation of tangible assets amounted to 2.6 MSEK.

Non-recurring items amounted to 8.8 MSEK, consisting of 1.5 MSEK relating to change of management, 3.8 to organization adjustments and 3.5 to other.

CEO comments:

As the Covid-19 situation has improved during end of the quarter, business begins to normalize. Our direct interaction with our customers is now increasing towards a more normalized level and we do see an increased customer activity.

2021 was a year with high focus on delivery and we have had really good progress in our development and implementation projects across the organisation. The pandemic highlighted the need for a modern and scalable vaccination journal system in Sweden and Cambio MittVaccin have signed contracts with 8 Swedish regions during 2021.

We continuously strive to enable our customers to improve patient safety and increase quality in health- and social care. That is why Cambio have invested in open standards and interoperability for many years which intensified during 2021. During second half of the year a contract was signed with Karolinska University Hospital for the implementation of a Clinical data repository.

We continue to make good progress across the organisation and are now very focused on implementing the Cambio strategy with a large focus on operational efficiency and productivity. Cambio is continuously focused on strengthening the partnerships with our customers to support them in their important work in the health- and social care sectors and to become even more efficient.

Rami Avidan, CEO

This disclosure contains information that Sanolium is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-02-2022 09:00 CET.

For further information, please contact: 

Jenny Styren 
Chief Marketing & Communication Officer 
+46 7 0 79 34 83 
jenny.styren@cambio.se

Sanolium AB, parent of the Cambio Group (“Cambio” or “the Company”) operating entities, is an e-health company providing comprehensive IT solutions to improve healthcare and patient safety. Cambio is one of the largest suppliers in Scandinavia and a growing player in the European market, with more than 170,000 users across regions and municipalities, general and university hospitals, health centers and specialist units. Cambio has offices in Sweden, Denmark, United Kingdom and Sri Lanka.